Shattuck Labs Q1 net loss widens as R&D spends rise

Shattuck Labs

07/05/2026 11:23

Overview

US biotechnology firm's Q1 net loss widened yr/yr as operating expenses increased

Company reported no revenue for Q1 2026

Cash and equivalents rose to $90.4 mln, expected to fund operations into 2029

Outlook

Shattuck expects to release Phase 1 SL-325 data in Q2 2026

Company expects to initiate Phase 2 SL-325 trial in Crohn's disease in Q3 2026

Shattuck expects current cash and equivalents to fund operations into 2029

Result Drivers

HIGHER R&D SPENDING - Q1 research and development expenses rose as company advanced clinical and preclinical programs

NO REVENUE - Company reported no revenue for Q1 2026 as it remains in clinical-stage development

Company press release: ID:nGNX6JrTg9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$14.77 mln
Q1 Basic EPS
-$0.13
Q1 Income From Operations
-$15.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Shattuck Labs Inc is $14.00, about 109.6% above its May 6 closing price of $6.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)